ONCODESIGN PRECISION MEDICINE S.A.

PRESS RELEASE

published on 03/05/2025 at 15:52, 2 months 25 days ago

Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors
Oncodesign Precision Medicine appoints Christophe Thurieau, Executive Director Research at Servier, as an independent member of the Board of Directors for a four-year term. Thurieau brings over 35 years of healthcare expertise to OPM

Board Of Directors Healthcare Christophe Thurieau Oncodesign Precision Medicine Servier
BRIEF

published on 03/05/2025 at 15:52, 2 months 25 days ago

Christophe Thurieau rejoint le Conseil d'Administration d'Oncodesign Precision Medicine

Biotechnologie Conseil D'administration Nomination Christophe Thurieau Oncodesign Precision Medicine
BRIEF

published on 03/05/2025 at 15:52, 2 months 25 days ago

Christophe Thurieau joins the Board of Directors of Oncodesign Precision Medicine

Board Of Directors Biotechnology Appointment Christophe Thurieau Oncodesign Precision Medicine
PRESS RELEASE

published on 03/05/2025 at 15:47, 2 months 25 days ago

Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors
Nomination de Christophe Thurieau en tant qu’administrateur indépendant du Conseil d’Administration d’OPM. Christophe Thurieau, expert en Recherche et Développement Pharmaceutique, rejoindra OPM pour un mandat de 4 ans

Biopharmaceutique Médecine De Précision Administrateur Indépendant OPM Christophe Thurieau
BRIEF

published on 10/15/2024 at 08:05, 7 months 15 days ago

OPM-101 Phase 1 Trial Results Presented at UEG Week 2024

Ulcerative Colitis Phase 1 Trial UEG Week 2024 OPM-101 Safety Profile
BRIEF

published on 10/15/2024 at 08:05, 7 months 15 days ago

Résultats de l'essai de phase 1 OPM-101 présentés à l'UEG Week 2024

Rectocolite Hémorragique Semaine UEG 2024 OPM-101 Essai De Phase 1 Profil De Sécurité
PRESS RELEASE

published on 10/15/2024 at 08:00, 7 months 15 days ago

Inside Information / Other news releases
OPM presents safety & efficacy data on OPM-101, a novel RIPK2 kinase inhibitor, in healthy volunteers at UEG Week 2024 conference, targeting IBD treatment

Precision Medicine UEG Week 2024 OPM-101 RIPK2 Kinase Inhibitor IBD Treatment

Published on 05/30/2025 at 15:30, 1 hour 48 minutes ago

Silver Spruce Signs Amended Option Agreement, Provides Exploration Update on Pino de Plata Project, Chihuahua, Mexico
Published on 05/30/2025 at 15:00, 2 hours 18 minutes ago

Future Fuels and VRIFY Forge Partnership to Advance District-Scale Uranium Exploration in Nunavut's Hornby Basin
Published on 05/30/2025 at 15:00, 2 hours 18 minutes ago

Nexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 05/30/2025 at 14:30, 2 hours 48 minutes ago

Abasca Resources Files NI 43-101 Technical Report on its Loki Flake Graphite Deposit Confirming Initial Resource Estimate
Published on 05/30/2025 at 14:30, 2 hours 48 minutes ago

Rio Grande Resources Announces Non-Brokered Private Placement

View all ACCESSWIRE

Published on 05/30/2025 at 17:00, 18 minutes ago

The Highlight Group publishes results for first quarter of 2025
Published on 05/30/2025 at 16:45, 33 minutes ago

Zentra Group plc: Trading Update
Published on 05/30/2025 at 16:43, 35 minutes ago

Annual Report for the 2024 financial year published
Published on 05/30/2025 at 16:38, 40 minutes ago

Coinsilium Group Limited: Total Voting Rights
Published on 05/30/2025 at 15:58, 1 hour 20 minutes ago

Coinsilium Group Limited: Early Close of WRAP Retail Offer

View all EQS

Published on 05/28/2025 at 23:00, 1 day 18 hours ago

Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 1 day 18 hours ago

Engagements collectifs de conservation de titres de la société
Published on 05/28/2025 at 18:39, 1 day 22 hours ago

Descriptif du programme de rachat d'actions - Mai 2025
Published on 05/28/2025 at 18:39, 1 day 22 hours ago

Description of share-buyback program - May 2025
Published on 05/28/2025 at 18:34, 1 day 22 hours ago

AXA a placé 1 milliard d’euros d’Obligations Restricted Tier 1 et 1 milliard d’euros d’Obligations Tier 2

View all LES ECHOS COMFI WIRE

News